Shelman Shelman

Dr. Shelman Shelman


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Abdominal Radiology
Verified
Journal Article
Open access
PDF file
RKRachita Khot
Rachita Khot
SSShelman Shelman
Shelman Shelman
DLDaniel R. Ludwig
Daniel R. Ludwig
RNRashmi T. Nair
Rashmi T. Nair
MAMark A. Anderson
Mark A. Anderson
CMChristine O. Menias
Christine O. Menias
Hepatic ductopenia is a pathologic diagnosis characterized by a decrease in the number of intrahepatic bile ducts as a consequence of various underlying etiologies. Some etiologies, such as primary sclerosing cholangitis, primary biliary cholangitis, and ischemic cholangitis, often have distinctive imaging findings. In contrast, other causes such as chronic rejection following liver transplantation, drug-induced biliary injury, infection, malignancy such as lymphoma, and graft-versus-host disease may only have ancillary or non-specific imaging findings. Thus, diagnosing ductopenia in conditions with nonspecific imaging findings requires a multidimensional approach, including clinical evaluation, serological testing, imaging, and liver histology to identify the underlying cause. These etiologies lead to impaired bile flow, resulting in cholestasis, liver dysfunction, and, ultimately, cirrhosis and liver failure if the underlying cause remains untreated or undetected. In the majority of instances, individuals diagnosed with ductopenia exhibit a positive response to treatment addressing the root cause or cessation of the causative agent. This article focuses on acquired causes of ductopenia, its clinical manifestation, histopathology, imaging diagnosis, and management. Graphical abstract

17 March 2026 in JCI Insight
Verified
Journal Article
Open access
PDF file
HTHeather E. True
Heather E. True
BDBrianna M. Doratt
Brianna M. Doratt
SWSheridan B. Wagner
Sheridan B. Wagner
DMDelphine C. Malherbe
Delphine C. Malherbe
SSShelman Shelman
Shelman Shelman
IMIlhem Messaoudi
Ilhem Messaoudi
Maternal opioid use disorder (OUD) poses substantial risks to maternal and fetal health. These adverse outcomes are believed to be mediated, in part, by changes in placental structure and function; however, few studies have addressed this question. Here, we utilized flow cytometry, histology, and spatial and single-cell transcriptomics to uncover the impact of OUD on placental tissues. Given that half of individuals with chronic OUD contract hepatitis C (HCV), we further stratified our findings by maternal HCV status. Our results indicate that OUD leads to higher incidence of vascular malperfusion accompanied by increased levels of inflammatory markers and dysregulated secretion of placental development factors. Spatial transcriptomics revealed that OUD disrupts the communication between trophoblasts and immune cells important for placental vascular development. Additionally, CellChat analysis revealed aberrant vascular remodeling, neuropeptide, and chemotactic signaling across trophoblast, endothelial, and myeloid cells. Processes associated with tissue homeostasis and repair were also upregulated across trophoblasts and leukocytes. In addition, placental leukocytes were rewired toward regulatory/tissue surveillant phenotypes. Finally, frequencies and responses to ex vivo stimulation of decidual macrophages and cytolytic NK cells, critical for tissue remodeling and fetal tolerance, were decreased. Altogether, these results highlight substantial disruptions to placental health by maternal OUD. Opioid use disorder during pregnancy disrupts placenta health with implications for adverse impacts to maternal and fetal health.

1 February 2026 in ACG Case Reports Journal
Verified
Journal Article
Open access
BABalkeess Alhanaktah
Balkeess Alhanaktah
ECEmad Chishti
Emad Chishti
SSShelman Shelman
Shelman Shelman
BIBahaaeldeen Ismail
Bahaaeldeen Ismail
Immunoglobulin G4-related disease is a chronic, systemic immune-mediated condition. Esophageal involvement is considered rare and often poses major diagnostic and therapeutic challenges. We present an 81-year-old male patient with isolated esophageal immunoglobulin G4-related disease with extended clinical and endoscopic follow-up for 6 years, who had poor tolerance to systemic and topical steroids. The patient was successfully treated using a combination of intralesional steroids and serial balloon dilations spaced at long intervals. This approach, which has not been previously reported in this condition, resulted in prolonged clinical stability over an extended period.

8 April 2025 in Children
Verified
Journal Article
Open access
IBIanna S. C. Blanchard
Ianna S. C. Blanchard
RBRavi Bhavsar
Ravi Bhavsar
AOAshley Marie Olszewski
Ashley Marie Olszewski
SSShelman Shelman
Shelman Shelman
JDJohn D'orazio
John D'orazio
TSThitinart Sithisarn
Thitinart Sithisarn
Background: Malignant Ectomesenchymoma (MEM) is a rare, aggressive soft tissue neoplasm with both neuroectodermal and mesenchymal differentiation. Congenital cases are extremely uncommon, posing significant diagnostic and therapeutic challenges. Case Presentation: We report a case of a full-term male neonate presenting with a large congenital neck mass and respiratory distress at birth. Imaging revealed a lobulated, heterogeneously enhancing mass in the left submandibular region with a mass effect on the airway. Open biopsy and gross resection on day six of life confirmed MEM with rhabdomyoblastic and neuroectodermal differentiation. Post-surgical staging classified the tumor as Stage I, Clinical Group II. Despite initial chemotherapy with Vincristine, Actinomycin, and Cyclophosphamide (VAC), tumor recurrence was detected at week nine of chemotherapy, necessitating a transition to Vincristine, Irinotecan, and Temozolomide (VIT). Discussion: MEM is an extremely rare neoplasm in infants, particularly in congenital presentations. Diagnosis is challenging due to its mixed histopathological features and broad differential diagnosis, including rhabdomyosarcoma, fibrosarcoma, lymphangioma, and neuroblastoma. Management typically involves multimodal therapy, with surgical resection being the mainstay of treatment. Chemotherapy is often tailored to the tumor’s most aggressive component, though standardized treatment protocols remain undefined. Conclusions: This case highlights the importance of early recognition and a multidisciplinary approach in managing congenital MEM, as a differential diagnosis of soft tissue masses in infants, particularly in the head and neck region.

27 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
NHNathaniel Charles Holcomb
Nathaniel Charles Holcomb
AHAmanda Harrington
Amanda Harrington
HPHong Pu
Hong Pu
BHBerina August Halilovic
Berina August Halilovic
SSShelman Shelman
Shelman Shelman
JDJohn D'orazio
John D'orazio
We identified a germline TP53 c.758C>T (p.T253I) mutation in the TP53 tumor suppressor gene in a pediatric adrenocortical carcinoma (ACC) patient. Characteristic to pathogenic p53 mutations, we observed upregulation of total p53 protein levels in the patient’s ACC and concurrent suppression of the wild-type (WT) TP53 allele. As ACC can be associated with Li-Fraumeni Syndrome (LFS) and the mutation has not yet been linked to LFS, we sought to characterize the functionality of the T253I mutation. We acquired p53 -/- HEK293 cells and stably transduced them with GFP-tagged wild type (T253) or T253I p53 as well as two established pathogenic p53 mutants (C176Y and R213X). Compared to p53 WT, levels of T253I p53 increased while MDM2 levels decreased, suggesting a loss of MDM2-mediated regulation of T253I p53. Additionally, T253I showed a reduction in DNA damage responsive events, diminished DNA binding capabilities, and blunted transactivation capacity. These experimental data lead us to conclude that T253I represents a pathologic variant in TP53 that may predispose to LFS-associated tumors.